Hemosol B0

Hemosol B0 is an intravenous dialysis solution containing calcium, lactic acid, magnesium, sodium, chloride ion, and hydrogen carbonate. It is supplied as a sterile solution for infusion during haemodialysis, providing electrolyte and bicarbonate buffering. The product is manufactured for the EU market and is prescribed for renal replacement therapy. It is intended for use under medical supervision and is classified as a prescription‑only electrolyte solution.

Hemosol B0 is used as the dialysate fluid during haemodialysis procedures to support patients with end‑stage renal disease.

- Provides calcium and magnesium to maintain plasma electrolyte levels during dialysis. - Supplies sodium and chloride to help regulate fluid balance. - Delivers hydrogen carbonate as a bicarbonate buffer to correct metabolic acidosis. - Supports overall acid‑base homeostasis throughout the treatment session. - Can be employed in continuous renal replacement therapy (CRRT) where compatible.

Adverse reactions to Hemosol B0 are generally uncommon, but patients may experience effects related to its electrolyte composition or buffering capacity.

Common: - Mild transient hypotension during infusion. - Slight nausea or vomiting. - Mild pruritus at the infusion site. - Temporary changes in serum calcium or magnesium levels.

Serious: - Severe hypercalcemia or hypermagnesemia. - Metabolic alkalosis from excessive bicarbonate. - Acute pulmonary edema due to fluid overload. - Anaphylactic or severe allergic reaction to the solution.

Clinicians should observe specific precautions when prescribing Hemosol B0 to ensure patient safety and optimal dialysis outcomes.

- Verify patient’s baseline electrolyte and acid‑base status before initiating treatment. - Adjust dialysate composition for patients with known hypercalcemia, hypermagnesemia, or severe metabolic alkalosis. - Monitor blood pressure and fluid balance closely during the session. - Use only with compatible haemodialysis machines and tubing sets. - Avoid use in patients with known hypersensitivity to any component of the solution. - Document any adverse events and report according to local regulations.

Hemosol B0 may interact with certain medications or clinical conditions, requiring careful management.

Avoid: - Concurrent administration of calcium channel blockers that may potentiate hypercalcemia. - High-dose vitamin D analogues that increase calcium absorption. - Sodium‑containing medications that could exacerbate fluid overload.

Use with caution: - Loop diuretics, as they may alter intravascular volume and electrolyte shifts. - ACE inhibitors or ARBs, which can affect potassium and blood pressure during dialysis. - Anticoagulants, because changes in calcium levels can influence coagulation pathways.